Get the Stockscreener App
1.155
2.12%
-0.025
After Hours:
1.16
0.005
+0.43%
Cardiol Therapeutics Inc stock is traded at $1.155, with a volume of 552.27K.
It is down -2.12% in the last 24 hours and up +11.06% over the past month.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
See More
Previous Close:
$1.18
Open:
$1.2
24h Volume:
552.27K
Relative Volume:
1.02
Market Cap:
$133.14M
Revenue:
-
Net Income/Loss:
$-26.33M
P/E Ratio:
-4.0899
EPS:
-0.2824
Net Cash Flow:
$-17.65M
1W Performance:
-6.48%
1M Performance:
+11.06%
6M Performance:
+15.50%
1Y Performance:
-19.79%
1-Day Range:
$1.15
$1.21
1-Week Range:
$1.15
$1.32
52-Week Range:
$0.88
$1.71
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.155 | 136.02M | 0 | -26.33M | -17.65M | -0.2824 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jun-26-24 | Initiated | ROTH MKM | Buy |
| Apr-22-24 | Initiated | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Stock (CRDL) Latest News
TradingKey - TradingKey
CRDL|Cardiol Therapeutics Inc|Price:1.180|Chg%:-0.050 - TradingKey
Cardiol Therapeutics Inc (CRDL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cardiol Therapeutics Inc (CRDL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardiol Therapeutics Inc (CRDL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cardiol Therapeutics Inc. Class A Revenue Breakdown – SWB:CT9 - TradingView
Why Cardiol Therapeutics Inc Class A stock is sliding today - Wealth Awesome
Cardiol Therapeutics (CRDL) Gains 4.13% as Bullish Momentum Builds Above $1.23 SupportDouble EMA - dars.gov.et
What's Going On With Cardiol Therapeutics Inc Class A Stock Monday? - Wealth Awesome
CRDL Stock Price, Quote & Chart - ChartMill
Why Cardiol Therapeutics Inc Class A stock is skyrocketing today - Wealth Awesome
Cardiol Therapeutics (TSX:CRDL) Expands Visibility Across Healthcare Sector - Kalkine Media
Why Cardiol Therapeutics Inc Class A stock is rising today - Wealth Awesome
Cardiol Therapeutics Publishes Recurrent Pericarditis Phase II Data - t.co
H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9 - Investing.com
H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9 By Investing.com - Investing.com Nigeria
Cardiol Therapeutics’ Phase II Pericarditis Data in JAHA Bolsters Near-Complete Phase III MAVERIC Trial - TipRanks
Cardiol Publishes Phase II MAVERIC Data in the Journal of the American Heart Association - the deep dive
Cardiol publishes phase II pericarditis study in medical journal By Investing.com - Investing.com South Africa
CRDL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $9 - GuruFocus
What's Going On With Cardiol Therapeutics Inc Class A Stock Tuesday? - Wealth Awesome
Cardiol Therapeutics Inc. - Baystreet.ca
Cardiol publishes phase II pericarditis study in medical journal - Investing.com
Cardiol Therapeutics (NASDAQ: CRDL) publishes Phase II pericarditis data as Phase III nears full enrollment - Stock Titan
CRDL SEC FilingsCardiol Therapeu 10-K, 10-Q, 8-K Forms - Stock Titan
Cardiol Therapeutics (CRDL) to Attend B. Riley Securities Summit in Boston - GuruFocus
Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit - 富途牛牛
Cardiol Therapeutics to Highlight CardiolRx Programs at B. Riley Mind, Muscle & Vision Summit - TipRanks
Cardiol Therapeutics (CRDL) to present CardiolRx™ pipeline at B. Riley Mind, Muscle & Vision Summit - Stock Titan
Why Cardiol Therapeutics Inc Class A stock is plummeting today - Wealth Awesome
ETFs Investing in Cardiol Therapeutics Inc. Class A Stocks - TradingView
Why Cardiol Therapeutics Inc Class A stock is gaining today - Wealth Awesome
Why Cardiol Therapeutics Inc Class A stock is tanking today - Wealth Awesome
CRDL Should I Buy - Intellectia AI
CRDL Q1 2026 Earnings: Narrower-than-Expected Loss as Cardiol Therapeutics Advances PipelineReturn On Equity - dars.gov.et
CRDL Q1 2026 Earnings: Narrower-Than-Expected Loss as Company Advances Clinical PipelineEstimate Uncertainty - DonanımHaber
CRDL Q1 2026 Earnings: Narrower-than-Expected Loss Signals Steady Clinical ProgressGAAP Earnings Report - dars.gov.et
Enterprise value to revenue forward of Cardiol Therapeutics Inc. – BOATS:CRDL - TradingView
Price to earnings forward of Cardiol Therapeutics Inc. Class A – TSX:CRDL - TradingView
Enterprise value to revenue forward of Cardiol Therapeutics Inc. Class A – TSX:CRDL - TradingView
Cardiol Therapeutics Inc. Class A Actuals & Estimates (TSX:CRDL) - TradingView
Cardiol Therapeutics Inc. Class A Actuals & Estimates (NEO:CRDL) - TradingView
CRDL Forecast — Price Target — Prediction for 2027 - TradingView
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
Cardiol Therapeutics Shareholders Back Board Slate and Auditor at 2026 AGM - TipRanks
A2PA9E Forecast — Price Target — Prediction for 2027 - TradingView
Strong shareholder support at Cardiol Therapeutics (CRDL) 2026 AGM as all directors elected - Stock Titan
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders - Finansavisen
Cardiol Therapeutics (CRDL) Q1 2026 Earnings: Narrower Loss Per Share Amid Clinical ProgressProfit Guidance Range - dars.gov.et
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.30%
2.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):